CPA
PHAT icon

Capital Performance Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

Capital Performance Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-29
Closed -$524 – 1970
2024
Q3 		$524 Buy
+29
New +$405 ﹤0.01% 2226

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital Performance Advisors's PHAT Position: Q4 2024 in Review

Capital Performance Advisors sold out of Phathom Pharmaceuticals (PHAT) in Q4 2024, closing a stake of 29 shares — an estimated $524 sold.

Capital Performance Advisors first reported a position in PHAT in Q3 2024 and held it in 1 quarter. The position peaked at $524 in Q3 2024. 144 funds tracked by Wall St. Rank hold PHAT as of Q4 2024.

  • Capital Performance Advisors reported no remaining Phathom Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 29 Phathom Pharmaceuticals shares in Q4 2024, an estimated $524.
  • Capital Performance Advisors first reported a position in Phathom Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Phathom Pharmaceuticals position peaked at $524 in Q3 2024.
  • 144 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.